Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update
-
Published:2018-11
Issue:11
Volume:36
Page:488-497
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Tsaur IgorORCID,
Heidegger Isabel,
Kretschmer AlexanderORCID,
Borgmann HendrikORCID,
Mirvald Cristian,
Gandaglia Giorgio,
Briganti Alberto,
van den Bergh Roderick,
Tilki Derya,
Ost Piet,
Ploussard GuillaumeORCID,
Surcel Cristian
Reference86 articles.
1. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients;Bubendorf;Hum Pathol,2000
2. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999
3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
4. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007);Norgaard;J Urol,2010
5. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool;Briganti;Eur Urol,2010